Pritelivir

Quenelle D. C, et al. Antiviral Research, 2018, 149, 1-6.

Pritelivir demonstrates potent antiviral activity against human herpes simplex virus (HSV) types 1 and 2, including acyclovir-resistant strains. In preclinical studies, pritelivir administered orally to mice with lethal HSV-1 and HSV-2 infections significantly reduced mortality, even when treatment was initiated 72 hours post-infection. The drug showed efficacy at dosages ranging from 0.3 to 30 mg/kg, with pritelivir improving survival rates by up to 70% in acyclovir-resistant strains, including HSV-1 strain 11360 and HSV-2 strain 12247. Combination therapy with pritelivir (0.1-0.3 mg/kg) and acyclovir (10 mg/kg) enhanced survival and extended the mean time to death, suggesting a synergistic effect. Pharmacokinetic analysis revealed dose-dependent pritelivir concentrations in both plasma and brain samples, confirming its systemic and central nervous system distribution. These findings highlight pritelivir's potential as a promising therapeutic for life-threatening HSV infections, including herpes simplex encephalitis, and underscore its ability to overcome acyclovir resistance.